Core Laboratories (CLB) to Release Earnings on Wednesday

Key Points

• Core Laboratories is set to release its Q3 2025 earnings after market close on October 22nd, with analysts expecting earnings of $0.18 per share and revenue of $130.924 million.
• The company reported a net margin of 5.73% and a return on equity of 14.15% in its last earnings release, along with a slight year-over-year revenue decline of 0.3%.
• Core Laboratories has a consensus rating of "Reduce" from analysts with a current price target of $12.50, reflecting mixed opinions on the stock's future performance.

Core Laboratories (NYSE:CLB - Get Free Report) is projected to release its Q3 2025 results after the market closes on Wednesday, October 22nd. Analysts expect Core Laboratories to post earnings of $0.18 per share and revenue of $130.9240 million for the quarter. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS.Individuals are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 23, 2025 at 8:30 AM ET.

Core Laboratories (NYSE:CLB - Get Free Report) last released its earnings results on Wednesday, July 23rd. The oil and gas company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.18 by $0.01. The firm had revenue of $130.16 million during the quarter, compared to analysts' expectations of $129.19 million. Core Laboratories had a net margin of 5.73% and a return on equity of 14.15%. Core Laboratories's revenue for the quarter was down .3% on a year-over-year basis. During the same period in the previous year, the company earned $0.22 EPS. On average, analysts expect Core Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Core Laboratories Price Performance

Shares of NYSE:CLB opened at $11.45 on Wednesday. The company has a market cap of $536.84 million, a P/E ratio of 18.47, a P/E/G ratio of 3.31 and a beta of 1.38. The company has a quick ratio of 1.70, a current ratio of 2.27 and a debt-to-equity ratio of 0.47. Core Laboratories has a 52 week low of $9.72 and a 52 week high of $21.83. The business has a fifty day simple moving average of $11.62 and a 200-day simple moving average of $11.82.

Core Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 25th. Shareholders of record on Monday, August 4th were issued a $0.01 dividend. The ex-dividend date was Monday, August 4th. This represents a $0.04 annualized dividend and a yield of 0.3%. Core Laboratories's payout ratio is 6.45%.

Hedge Funds Weigh In On Core Laboratories

Several large investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company lifted its holdings in Core Laboratories by 6.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company's stock worth $207,000 after buying an additional 1,040 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Core Laboratories by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company's stock worth $418,000 after purchasing an additional 1,170 shares during the last quarter. Captrust Financial Advisors lifted its stake in Core Laboratories by 11.8% during the second quarter. Captrust Financial Advisors now owns 37,401 shares of the oil and gas company's stock worth $431,000 after purchasing an additional 3,936 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Core Laboratories by 400.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,333 shares of the oil and gas company's stock worth $84,000 after buying an additional 5,869 shares during the last quarter. Finally, Public Sector Pension Investment Board lifted its position in shares of Core Laboratories by 7.4% in the 2nd quarter. Public Sector Pension Investment Board now owns 159,437 shares of the oil and gas company's stock worth $1,837,000 after buying an additional 10,961 shares during the last quarter. Institutional investors own 97.81% of the company's stock.

Wall Street Analysts Forecast Growth

CLB has been the subject of a number of recent analyst reports. Stifel Nicolaus lowered their target price on shares of Core Laboratories from $13.00 to $12.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. Zacks Research raised shares of Core Laboratories from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Wall Street Zen raised Core Laboratories from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of Core Laboratories in a report on Wednesday, October 8th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and a consensus price target of $12.50.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.